ENZ

Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update

Retrieved on: 
Wednesday, March 13, 2024
YTD, Drug development, Sale, ENZ, Corporation, Fine chemical

FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024.

Key Points: 
  • FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024.
  • During the 2024 period, we experienced a 25% revenue increase in the United States, driven by increased product demand in the drug development and cell and gene therapy market segments.
  • Revenue for the six months ended January 31, 2024 of $16.4 million improved 12% compared to the same period in the prior year.
  • The six-month YTD margin was 47% which was also a 1,000 basis point improvement compared to the prior year.

Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments

Retrieved on: 
Thursday, February 1, 2024
ENZ, Annual general meeting

FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments.

Key Points: 
  • FARMINGDALE, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments.
  • Proposal One – The shareholders elected Kara Cannon, Steven J. Pully, Bradley L. Radoff, and Mary Tagliaferri, M.D.
  • to the Company’s Board of Directors to hold office for a term ending as of our Fiscal 2024 annual meeting of shareholders, and until each such director’s successor is elected and qualified.
  • Proposal Two – The shareholders did not approve, by a non-binding advisory vote, the compensation of the Company’s named Executive Officers.

ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE

Retrieved on: 
Friday, December 15, 2023
Growth, ENZ, Corporation, Sale

FARMINGDALE, NY, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the first quarter ended October 31, 2023.

Key Points: 
  • FARMINGDALE, NY, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the first quarter ended October 31, 2023.
  • The Company's Life Sciences division's first quarter revenue improved year-over-year by 10% driven by increased demand in multiple product areas, and stability in our multi-pronged channel to market approach.
  • The Life Sciences division's first quarter gross margin was 44.3%, which improved sequentially and year-over-year by approximately 900 basis points.
  • Enzo’s working capital improved from $58.5 million at July 31, 2023 to $59.2 million at October 31, 2023.

ENZO BIOCHEM REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 RESULTS AND PROVIDES BUSINESS UPDATE

Retrieved on: 
Monday, November 6, 2023
Sale, NYSE, National Health Laboratory Service, RNA, ENZ, Corporation, Drug development, Audit committee, Interim, Health, Enzo, Culture, GMP, Fine chemical, Video game, Retail

FARMINGDALE, NY, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fourth quarter ended July 31, 2023, and the fiscal year ended July 31, 2023, and also provided a general business update.

Key Points: 
  • FARMINGDALE, NY, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fourth quarter ended July 31, 2023, and the fiscal year ended July 31, 2023, and also provided a general business update.
  • Enzo Life Sciences’ fourth quarter revenue improved sequentially by 20%, and year over year by 13%, driven by increased demand in multiple product areas and certain key customers.
  • The Industrial market increased 48% compared to the prior year’s fourth quarter driven by the increased focus of our experienced sales team.
  • Enzo ended the fourth quarter with aggregate cash and cash equivalents and restricted cash of $83.4 million.

Steven J. Pully Appointed to Enzo Biochem’s Board of Directors

Retrieved on: 
Monday, October 30, 2023
Bank, NYSE, FINRA, CPA, ENZ, Bear Stearns, Senior, Growth, Bank of America, Chartered Financial Analyst, Executive, Restaurant, Chairperson, Partner, Enzo, General counsel, Audit committee, Management

FARMINGDALE, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) --  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading life sciences company, announced today that Steven J. Pully has been appointed to the Company’s Board of Directors effective October 26, 2023.

Key Points: 
  • FARMINGDALE, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) --  Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading life sciences company, announced today that Steven J. Pully has been appointed to the Company’s Board of Directors effective October 26, 2023.
  • Mr. Pully will assume the role of Chairperson of the Board, and Chair of the Audit Committee as well.
  • “In 2023, Enzo completed the divestiture of Enzo Clinical Labs, Inc. and focused its strategy on growing the life sciences division,” said Kara Cannon, Enzo’s Chief Executive Officer.
  • Mr. Pully is also an attorney and CPA, he is a Chartered Financial Analyst, and he also holds various FINRA licenses.

The Radoff-Sudbury Group Files Definitive Proxy and Issues Letter to LifeVantage Corporation Stockholders

Retrieved on: 
Tuesday, September 26, 2023
Professional Services, Finance, Professional Football Compensation Committee, Marketing, Compensation, Protandim, McKinsey & Company, Audit committee, Investment, Bain & Company, NYSE, CARD, DOSH, Portfolio manager, Face, Third Point Management, America First Field, Bain, Coffee, Growth, Entrepreneurship, System, TSR, BLUE, Rule, HHS, Farmer, RLJE, INFO, ENZ, Audit, Foot, EBITDA, ANY, Annual general meeting, Tea, RLJE Films, LP, Cryptocurrency, Management, Vaccine, Security (finance), Holding company, Financial services, Financial adviser, Real Salt Lake

The LifeVantage Board, under Mr. Mauro’s leadership as Chairman, has been delivering persistently poor performance for over a decade.

Key Points: 
  • The LifeVantage Board, under Mr. Mauro’s leadership as Chairman, has been delivering persistently poor performance for over a decade.
  • And though revenue levels have recently steadied, in our view, there is not enough accountability at the Board-level to generate meaningful returns for stockholders.
  • Over the past several years, the number of LifeVantage distributors and active customers has been in perpetual decline.
  • Stockholders should look no further than LifeVantage’s 10-year, $30 million deal inked with major league soccer team Real Salt Lake for jersey and stadium sponsorship.

Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO

Retrieved on: 
Wednesday, September 6, 2023
Growth, ENZ, MD, NYSE, Management

FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) --  Enzo Biochem, Inc. (NYSE: ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo’s Chief Operating Officer, Kara Cannon, assuming the role of interim CEO.

Key Points: 
  • FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) --  Enzo Biochem, Inc. (NYSE: ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo’s Chief Operating Officer, Kara Cannon, assuming the role of interim CEO.
  • “We thank Hamid for the commitment he has brought to Enzo Biochem, Inc.”  Chairperson of the Board Mary Tagliaferri, MD stated, “Hamid successfully led the Company through the divestiture of Enzo Clinical Lab, Inc.  We wish him well in all his future endeavors and are excited to focus on the life sciences division.
  • We are confident in Kara to lead the Company forward during this transition.
  • Ms. Cannon stated, “I am appreciative to the Board of Directors for the opportunity to unlock the full potential of Enzo Life Sciences through the expansion of our product line and growth in sales.

Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp

Retrieved on: 
Monday, July 24, 2023
ENZ, McDermott Will & Emery, LH, Sale, Jefferies Group, MUFG Americas Holdings Corporation, Patient, Physician, NYSE, Pharmaceutical industry, Labcorp, Enzo

FARMINGDALE, NY, July 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has closed a transaction to sell certain assets of Enzo’s Clinical laboratory division (Enzo Clinical Labs) to Laboratory Corporation of America Holdings (Labcorp) (NYSE:LH) pursuant to an Asset Purchase Agreement dated March 16, 2023, as amended July 3, 2023.

Key Points: 
  • FARMINGDALE, NY, July 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has closed a transaction to sell certain assets of Enzo’s Clinical laboratory division (Enzo Clinical Labs) to Laboratory Corporation of America Holdings (Labcorp) (NYSE:LH) pursuant to an Asset Purchase Agreement dated March 16, 2023, as amended July 3, 2023.
  • Enzo Biochem has completed the previously announced transaction to sell substantially all of the assets located in the New York metropolitan region used in the operation of Enzo Clinical Labs to Labcorp for an aggregate purchase price of $113,250,000 in cash, subject to customary closing adjustments.
  • In accordance with the sale, Enzo Biochem will cease its clinical laboratory operations.
  • “The closing of this asset sale demonstrates our commitment to enhancing shareholder value,” said Hamid Erfanian, CEO of Enzo Biochem.

Enzo Biochem Reports Third Quarter Fiscal Year 2023 Financial Results

Retrieved on: 
Thursday, June 15, 2023
ENZ, Policy, Form 10-Q, COVID, Sale, Jefferies Group, Acquisition, Collection, Labcorp, NYSE, Pharmaceutical industry

FARMINGDALE, NY, June 14, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, today filed its Form 10-Q for the third quarter ended April 30, 2023 of Fiscal Year 2023 (Q3 FY23). Enzo Biochem will not be hosting a financial webcast or call for this most recent quarterly reporting period.

Key Points: 
  • - Enzo Life Sciences reports revenue of $7.5 million, with margin improvement in Q3 FY23
    FARMINGDALE, NY, June 14, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, today filed its Form 10-Q for the third quarter ended April 30, 2023 of Fiscal Year 2023 (Q3 FY23).
  • Enzo Biochem will not be hosting a financial webcast or call for this most recent quarterly reporting period.
  • As previously reported, on March 16, 2023, Enzo Biochem announced that Labcorp would purchase substantially all of the operating assets and certain liabilities of the Enzo Clinical Labs division.
  • Enzo Life Sciences anticipated continuous growth this quarter, however, revenues for Enzo Life Sciences were negatively impacted by the downtime period after the ransomware attack.

Enzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset Sale

Retrieved on: 
Monday, May 22, 2023
Sale, 2013 New Zealand asset sales referendum, ENZ, Election, NYSE, Security (finance), Management

FARMINGDALE, NY, May 22, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), announced today that  the preliminary voting results from the Inspector of Election at today’s Special Meeting of the Shareholders indicate that the Asset Sale Proposal was approved by the affirmative vote of a majority of Enzo’s outstanding common stock.

Key Points: 
  • FARMINGDALE, NY, May 22, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), announced today that  the preliminary voting results from the Inspector of Election at today’s Special Meeting of the Shareholders indicate that the Asset Sale Proposal was approved by the affirmative vote of a majority of Enzo’s outstanding common stock.
  • Pending final results of the vote, Enzo will have obtained shareholder approval and met all regulatory requirements for closing the sale of substantially all of the operating assets and assignment of certain liabilities of Enzo’s Clinical Labs division.
  • “We are grateful for the continuous support from our shareholders, many of whom have placed their trust in the Company for many years,” said Hamid Erfanian, CEO of Enzo Biochem.
  • “With the support of our shareholders for the asset sale, we look forward to advancing the Company’s “focused return” initiative and maximizing shareholder value in its next phase.”